

October 22, 2024

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 543322

Ref: Scrip Name: GLS

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 31A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (SEBI Listing Regulations) – Re-classification from ‘Promoter Group’ Category to ‘Public category’ of Glenmark Life Sciences Limited (‘the Company’)

Pursuant to Regulation 31A of the SEBI Listing Regulations, we wish to inform you that the BSE Limited (‘BSE’) and National Stock Exchange of India Limited (‘NSE’) vide their respective letters dated October 22, 2024, have granted their approval for re-classification of following outgoing promoters from ‘Promoter & Promoter Group’ Category to ‘Public Shareholders’ of the Company:

Sr. No.	Name	No. of equity shares held and % of shareholding
1.	Glenmark Pharmaceuticals Limited	-
2.	Mr. Glenn Mario Saldanha	-

Consequently, Glenmark Pharmaceuticals Limited and Mr. Glenn Mario Saldanha are now re-classified as ‘public shareholder’ with immediate effect and will not be reported as member of promoter & promoter group in the shareholding pattern that will be filed with the Stock Exchange under Regulation 31 of the SEBI Listing Regulations, going forward.

The approval Letter of BSE and NSE are enclosed herewith for your reference.

Thanking You,

Yours faithfully,
For Glenmark Life Sciences Limited

Rudalf Corriea
Company Secretary & Compliance Officer
Encl: As above

Glenmark Life Sciences Limited

Corporate Office: 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai 400 099, India.

Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpath, Solapur - 413 213, India.

T: 91 22 68297979 CIN: L74900PN2011PLC139963 E: complianceofficer@glenmarklifesciences.com W: www.glenmarklifesciences.com

National Stock Exchange Of India Limited

Ref: NSE/LIST/377

October 22, 2024

The Company Secretary
Glenmark Life Sciences Limited
Plot No 170-172
Chandramouli Industrial Estate
Mohol Solapur-413213

Subject: Approval for Reclassification of Promoters under Regulation 31A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

This has reference to your application dated March 22, 2024, seeking Reclassification of Promoters under the provisions of Regulation 31A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Based on submissions made by the company, the Exchange is pleased to approve your application for reclassification of following Promoter/ Promoter Group to Public as per the provisions of Regulation 31A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Sr. No.	Name of Shareholder
1	Glenmark Pharmaceuticals Limited
2	Glenn Mario Saldanha

You are required to ensure that the event of reclassification shall be disclosed to the Exchange as a material event in accordance with the provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Yours faithfully,
For **National Stock Exchange of India Ltd.**

Raksha Jain
Senior Manager

CC: **National Securities Depository Limited** **Central Depository Services Limited**
4th Floor, Trade world,
Kamala Mills Compound,
Senapati Bapat Marg.,
Lower Parel, Mumbai - 400 013 Marathon Futurex, A-Wing,
25th floor, NM Joshi Marg,
Lower Parel, Mumbai-400 073

LIST/COMP/AK/1378/2024-25

October 22, 2024

The Company Secretary/ Compliance Officer

Glenmark Life Sciences Ltd

Plot No. 170-172, Chandramouli Industrial Estate,
Mohol Bazarpeth, Solapur - 413 213, India.

Sub: Approval letter for Reclassification of Shareholders under Regulation 31A(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

We refer to your application dated March 22, 2024 seeking Reclassification of Promoter Shareholders under the provisions of Regulation 31A(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Exchange is pleased to approve your application for Reclassification of Promoter Shareholders under the provisions of Regulation 31A(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 based on submissions made by the company.

Entities mentioned in Annexure 1 shall be classified as public shareholders


The summary of the Shareholding Pre-Reclassification & Post-Reclassification is as follows:

Quarter	Promoter holding		Public Holding	
	Shares Held	Percentage	Shares Held	Percentage
Pre-Reclassification	9,18,96,285	75.00	3,06,32,387	25.00
Post-Reclassification	9,18,96,285	75.00	3,06,32,387	25.00

Reclassification of Promoters: **Glenmark Life Sciences Ltd**

This letter may be forwarded to the depositories and your RTA for necessary action at their end.

Yours faithfully,



Shyam Bhagirath
Manager
Listing Compliance



Rohan Kallan
Assistant Manager
Listing Compliance

Encl. Annexure 1 - Details of Outgoing Promoters

Annexure 1 – Details of Outgoing Promoters

ANNEXURE I			
Sr. No.	Outgoing promoter	No. of Shares	% Shareholding
1.	Glenn Mario Saldanha	0	0
2.	Glenmark Pharmaceuticals Limited	0	0
TOTAL		0	0.00

Reclassification of Promoters: **Glenmark Life Sciences Ltd**